# DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

> **NIH NIH N01** · CERAMEDIX HOLDING, LLC · 2024 · $1,427,108

## Abstract

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.

## Key facts

- **NIH application ID:** 11118646
- **Project number:** 75N93023C00015-P00003-9999-1
- **Recipient organization:** CERAMEDIX HOLDING, LLC
- **Principal Investigator:** CHARLES DIMMLER III
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,427,108
- **Award type:** —
- **Project period:** 2023-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11118646

## Citation

> US National Institutes of Health, RePORTER application 11118646, DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE (75N93023C00015-P00003-9999-1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/11118646. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*